

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/661,455		
		Filing Date	September 12, 2003		
		First Named Inventor	NAKORN, THANYAPHONG NA		
		Art Unit			
Sheet	1	of	2	Examiner Name	
				Attorney Docket Number	STAN-278

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
leb		US- 6,485,247		Oct. 15, 2002	Weissman et al.	
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					


OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), <small>publisher, city and/or country where published</small>	T ²
leb		AKASHI <i>et al.</i> , A CLONOGENIC COMMON MYELOID PROGENITOR THAT GIVES RISE TO ALL MYELOID LINEAGES, <i>Nature</i> , (2000), 404, 193-197 -	
		BURSTEIN <i>et al.</i> , CHARACTERISTICS OF MURINE MEGAKARYOCYTIC COLONIES IN VITRO, <i>Blood</i> , (1979), 54, 169-179 -	
		ENVER <i>et al.</i> , DO STEM CELLS PLAY DICE?, <i>Blood</i> , (1998), 92, 348-351 -	
		GEORGOPOULOS <i>et al.</i> , THE ROLE OF IKAROS GENE IN LYMPHOCYTE DEVELOPMENT AND HOMEOSTASIS, <i>Annu. Rev. Immunol.</i> , (1997), 15:155-176 -	
		LONG <i>et al.</i> , IMMATURE MEGAKARYOCYTES IN THE MOUSE: IN VITRO RELATIONSHIP TO MEGAKARYOCYTE PROGENITOR CELLS AND MATURE MEGAKARYOCYTES, <i>J. Cell. Physiol.</i> , (1982), 112, 339-344 -	

Examiner Signature		Date Considered	4/6/06
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/661,455		
		Filing Date	September 12, 2003		
		First Named Inventor	NAKORN, THANYAPHONG NA		
		Group Art Unit			
Sheet	2	of	2	Examiner Name	
				Attorney Docket Number	STAN-278

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Ceb		LONG <i>et al.</i> , ROLE OF PHORBOL DIESTERS IN IN VITRO MURINE MEGAKARYOCYTE COLONY FORMATION, <i>J. Clin. Invest.</i> , (1984), 74, 1686-1692 -	
		MORRISON <i>et al.</i> , THE AGING OF HEMATOPOIETIC STEM CELLS, <i>Nat Med</i> , (1996), 2, 1011-1016 -	
		MORRISON <i>et al.</i> , THE LONG-TERM REPOPULATING SUBSET OF HEMATOPOIETIC STEM CELLS IS DETERMINISTIC AND ISOLATABLE BY PHENOTYPE, <i>Immunity</i> , (1994), 1, 661-673 -	
		NA NAKORN <i>et al.</i> , MYELOERYTHROID-RESTRICTED PROGENITORS ARE SUFFICIENT TO CONFER RADIOPROTECTION AND PROVIDE THE MAJORITY OF DAY 8 CFU-S, <i>J. Clin. Invest.</i> , (2002), 109, 1579-1585 -	
		ORKIN <i>et al.</i> , DEVELOPMENT OF THE HEMATOPOIETIC SYSTEM, <i>Curr. Opin. Genet. Dev.</i> , (1996) 6:597-602 -	
		PAULUS <i>et al.</i> , POLYPLOID MEGAKARYOCYTES DEVELOP RANDOMLY FROM A MULTICOMPARTMENTAL SYSTEM OF COMMITTED PROGENITORS, <i>Proc. Natl. Acad. Sci. USA</i> , (1982), 79, 4410-4414 -	
		SINGH <i>et al.</i> , GENE TARGETING REVEALS A HIERARCHY OF TRANSCRIPTION FACTORS REGULATING SPECIFICATION OF LYMPHOID CELL FATES, <i>Curr. Opin. Immunol.</i> , (1996), 8:160-165 -	
		SPANGRUDE <i>et al.</i> PURIFICATION AND CHARACTERIZATION OF MOUSE HEMATOPOIETIC STEM CELLS, <i>Science</i> , (1988), 241, 58-62 -	
		UCHIDA <i>et al.</i> , RAPID AND SUSTAINED HEMATOPOIETIC RECOVERY IN LETHALLY IRRADIATED MICE TRANSPLANTED WITH PURIFIED THY-1.1 ^{lo} LIN ^{SCA-1} ⁺ HEMATOPOIETIC STEM CELLS, <i>Blood</i> , (1994), 83, 3758-3779 -	

Examiner Signature		Date Considered	4/6/06
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/661,455		
		Filing Date	September 12, 2003		
		First Named Inventor	NAKORN, THANYAPHONG NA		
		Art Unit			
Sheet	1	of	1	Examiner Name	
				Attorney Docket Number	STAN-278

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
Cey		US- 2002/0086422	07-04-02	WEISSMAN	
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
Cey		BANU et al., MODULATION OF HAEMATOPOIETIC PROGENITOR DEVELOPMENT BY FLT-3 LIGAND, Cytokine, 1999, 11(9): 679-688	
		GUERRIERO et al., UNILINEAGE MEGAKARYOCYTIC PROLIFERATION AND DIFFERENTIATION OF PURIFIED HEMATOPOIETIC PROGENITORS IN SERUM-FREE LIQUID CULTURE, Blood, 1995, 86(10): 3725-3736	
✓		TAO et al., MEGAKARYOCYTOPOIESIS: CORD BLOOD IS BETTER THAN BONE MARROW FOR GENERATING MEGAKARYOCYTIC PROGENITOR CELLS, Exp. Hematol., 1999, 27: 293-301	

Examiner Signature		Date Considered	4/6/06
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.